Gables Capital Management Inc. Catalyst Pharmaceuticals, Inc. Transaction History

Gables Capital Management Inc.

$207 Million
Q2 2025

A detailed history of Gables Capital Management Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Gables Capital Management Inc. holds 409,021 shares of CPRX stock, worth $8.12 Million. This represents 4.28% of its overall portfolio holdings.

Number of Shares

409,021

Previous 416,371 1.77%

Holding current value

$8.12 Million

Previous $10.1 Million 12.09%

% of portfolio

4.28%

Previous 5.08%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 30, 2025	SELL	$21.4 - $26.31 $157,290 - $193,378	-7,350 Reduced 1.77%	409,021 $8.88 Million
Q1 2025 May 08, 2025	SELL	$19.53 - $25.74 $23,045 - $30,373	-1,180 Reduced 0.28%	416,371 $10.1 Million
Q4 2024 Feb 07, 2025	SELL	$19.73 - $23.93 $191,381 - $232,121	-9,700 Reduced 2.27%	417,551 $8.71 Million
Q3 2024 Oct 24, 2024	SELL	$15.19 - $21.35 $75,327 - $105,874	-4,959 Reduced 1.15%	427,251 $8.49 Million
Q2 2024 Aug 07, 2024	SELL	$14.68 - $16.92 $65,326 - $75,294	-4,450 Reduced 1.02%	432,210 $6.69 Million
Q1 2024 May 03, 2024	BUY	$13.18 - $17.11 $31,632 - $41,064	2,400 Added 0.55%	436,660 $6.96 Million
Q4 2023 Feb 07, 2024	BUY	$11.78 - $17.29 $27,152 - $39,853	2,305 Added 0.53%	434,260 $7.3 Million
Q3 2023 Nov 02, 2023	SELL	$11.69 - $15.02 $34,777 - $44,684	-2,975 Reduced 0.68%	431,955 $5.05 Million
Q2 2023 Aug 02, 2023	BUY	$11.5 - $18.08 $297,275 - $467,367	25,850 Added 6.32%	434,930 $5.85 Million
Q1 2023 May 03, 2023	SELL	$14.34 - $21.05 $193,948 - $284,701	-13,525 Reduced 3.2%	409,080 $6.78 Million
Q4 2022 Feb 03, 2023	SELL	$12.25 - $19.5 $137,310 - $218,575	-11,209 Reduced 2.58%	422,605 $7.86 Million
Q3 2022 Oct 31, 2022	SELL	$7.06 - $15.52 $13,767 - $30,264	-1,950 Reduced 0.45%	433,814 $5.57 Million
Q2 2022 Jul 18, 2022	SELL	$6.23 - $8.57 $18,690 - $25,710	-3,000 Reduced 0.68%	435,764 $3.06 Million
Q1 2022 May 02, 2022	SELL	$5.31 - $8.31 $55,223 - $86,424	-10,400 Reduced 2.32%	438,764 $3.64 Million
Q4 2021 Feb 09, 2022	BUY	$5.21 - $7.45 $300,096 - $429,120	57,600 Added 14.71%	449,164 $3.04 Million
Q3 2021 Nov 12, 2021	BUY	$4.85 - $6.04 $240,559 - $299,584	49,600 Added 14.5%	391,564 $2.08 Million
Q2 2021 Aug 03, 2021	SELL	$4.29 - $6.05 $279,279 - $393,855	-65,100 Reduced 15.99%	341,964 $1.97 Million
Q1 2021 May 12, 2021	SELL	$3.45 - $4.69 $21,735 - $29,547	-6,300 Reduced 1.52%	407,064 $1.88 Million
Q4 2020 Feb 03, 2021	SELL	$2.97 - $3.83 $57,915 - $74,685	-19,500 Reduced 4.5%	413,364 $1.38 Million
Q3 2020 Nov 12, 2020	SELL	$2.97 - $5.08 $219,780 - $375,920	-74,000 Reduced 14.6%	432,864 $1.29 Million
Q2 2020 Jul 30, 2020	SELL	$3.48 - $5.05 $20,880 - $30,300	-6,000 Reduced 1.17%	506,864 $2.34 Million
Q1 2020 May 07, 2020	SELL	$2.61 - $5.21 $13,050 - $26,050	-5,000 Reduced 0.97%	512,864 $1.98 Million
Q4 2019 Feb 10, 2020	BUY	$3.67 - $5.7 $100,191 - $155,610	27,300 Added 5.57%	517,864 $1.94 Million
Q3 2019 Oct 30, 2019	BUY	$3.89 - $7.43 $17,505 - $33,435	4,500 Added 0.93%	490,564 $2.61 Million
Q2 2019 Jul 31, 2019	BUY	$2.7 - $6.11 $17,010 - $38,493	6,300 Added 1.31%	486,064 $1.87 Million
Q1 2019 Apr 30, 2019	SELL	$2.11 - $5.33 $2,110 - $5,330	-1,000 Reduced 0.21%	479,764 $2.45 Million
Q4 2018 Feb 08, 2019	BUY	$1.92 - $3.62 $62,400 - $117,650	32,500 Added 7.25%	480,764 $923,000
Q3 2018 Nov 05, 2018	BUY	$2.81 - $3.78 $8,430 - $11,340	3,000 Added 0.67%	448,264 $0
Q2 2018 Aug 03, 2018	SELL	$2.26 - $3.84 $30,735 - $52,224	-13,600 Reduced 2.96%	445,264 $1.51 Million
Q1 2018 May 17, 2018	BUY	$2.39 - $4.01 $1.1 Million - $1.84 Million	458,864 New	458,864 $1.1 Million

Others Institutions Holding CPRX

# of Institutions

389

Shares Held

100M

Call Options Held

37K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.04B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gables Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gables Capital Management Inc. with notifications on news.

Account

Gables Capital Management Inc. Catalyst Pharmaceuticals, Inc. Transaction History